

1 TITLE

2 **Japanese Project for Telepsychiatry Evaluation during COVID-19: Treatment Comparison**

3 **Trial (J-PROTECT): Rationale, design, and methodology**

4 Taishiro Kishimoto ^a, Shotaro Kinoshita ^{a,b}, Shogyoku Bun ^{c,d}, Yasunori Sato ^e, Momoko Kitazawa ^c, Toshiaki

5 Kikuchi ^c, Mitsuhiro Sado ^c, Akihiro Takamiya ^c, Masaru Mimura ^c, Takashi Nakamae ^f, Yoshinari Abe ^f,

6 Tetsufumi Kanazawa ^g, Yasuo Kawabata ^g, Hiroaki Tomita ^{h,i}, Koichi Abe ^h, Akitoyo Hishimoto ^j, Takeshi Asami

7 ^j, Akira Suda ^j, Yoshinori Watanabe ^k, Toru Amagai ^l, Kei Sakuma ^m, Hisashi Kida ^{c,m}, Michitaka Funayama ⁿ,

8 Hiroshi Kimura ^{o,p}, Aiko Sato ^p, Shuichiro Fujiwara ^q, Kiichiro Nagao ^r, Naoya Sugiyama ^s, Maki Takamiya

9 ^t, Hideyuki Kodama ^t, Takaharu Azekawa ^u, on behalf of the J-PROTECT collaborators

10

11 **Affiliations:**

12 ^a Hills Joint Research Laboratory for Future Preventive Medicine and Wellness, Keio University School of
13 Medicine, #7F Roppongi Hills North Tower 6-2-31 Roppongi, Minato-ku, Tokyo 106-0032, Japan

14 ^b Graduate School of Medicine, International University of Health and Welfare, 4-1-26 Akasaka, Minato-ku,
15 Tokyo, 107-8402, Japan

16 ^c Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo,
17 160-8582, Japan

18 ^d Sato Hospital, 948-1 Kunugizuka, Nanyo, Yamagata, 999-2221, Japan

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

19 ^e Department of Preventive Medicine and Public Health, Keio University School of Medicine, 35
20 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan

21 ^f Department of Psychiatry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine,
22 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo, Kyoto, Kyoto, 602-8566, Japan.

23 ^g Department of Neuropsychiatry, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi,
24 Takatsuki, Osaka, 569-8686. Japan.

25 ^h Department of Psychiatry, Tohoku University Hospital, 1-1 Seiryō-Machi, Aoba-ku, Sendai, Miyagi, 980-
26 8573, Japan.

27 ⁱ Department of Psychiatry, Tohoku University Graduate School of Medicine, 1-1 Seiryō-Machi, Aoba-ku,
28 Sendai, Miyagi, 980-8573, Japan.

29 ^j Department of Psychiatry, Yokohama City University Graduate School of Medicine, 3-9 Fukuura,
30 Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan

31 ^k Himorogi Psychiatric Institute, Ichigaya-Asukara Bldg. 1F2F, 2-31-3 Ichigayatamachi, Shinjuku, Tokyo
32 162-0843, Japan

33 ^l Amagai Mental Clinic, Kitami Bldg. 3F, 1-4-20 Kamiooka-nishi, Konan, Yokohama, Kanagawa, 233-0002,
34 Japan

35 ^m Asaka Hospital, 45 Kyotan, Sasagawa, Asakamachi, Koriyama, Fukushima, 963-0198, Japan

36 ⁿ Department of Neuropsychiatry, Ashikaga Red Cross Hospital, 284-1 Yobe, Ashikaga, Tochigi, 326-0843,

37 Japan

38 ^o Department of Psychiatry, Gakuji-kai Kimura Hospital, 6-19, Higashi Honcho, Chuo-ku, Chiba, Chiba, 260-
39 0004, Japan.

40 ^p Department of Psychiatry, School of Medicine, International University of Health and Welfare, 4-3,
41 Kozunomori, Narita, Chiba, 286-8686, Japan

42 ^q Kanazawabunko Yell Clinic, KANAZAWA BUNKO PARK HOMES 102, Kamariyahigashi, Kanazawa,
43 Yokohama, Kanagawa, 236-0042, Japan.

44 ^r Neyagawa Sanatoriumu, 2370-6 Neyagawakoen, Neyagawa, Osaka, Osaka, 572-0854, Japan

45 ^s Numazu Chuo Hospital, 24-1 Nakase-cho, Numazu, Shizuoka, 410-8575, Japan

46 ^t Takamiya Hospital, 1931 Omachikou, Yoshimura, Miyazaki, Miyazaki, 880-0841, Japan

47 ^u Shioiri Mental Clinic, 2-7-1 Shioiri, Yokosuka, Kanagawa, 238-0042, Japan

48

49

50

51

52 **Corresponding author:**

53 Taishiro Kishimoto, M.D., Ph.D.

54 Department of Neuropsychiatry, Keio University School of Medicine

55 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan

56 Email: taishiro-k@mti.biglobe.ne.jp

57 Phone: +81.3.5363.3829

58 Fax: +81.3.5379.0187

59

60

61 **ABSTRACT**

62 **Introduction:** The COVID-19 pandemic has had a profound impact on the mental health of people around the
63 world. Anxiety related to infection, stress and stigma caused by the forced changes in daily life have reportedly
64 increased the incidence and symptoms of depression, anxiety disorder and obsessive-compulsive disorder.
65 Under such circumstances, telepsychiatry is gaining importance and attracting a great deal of attention. However,
66 few large pragmatic clinical trials on the use of telepsychiatry targeting multiple psychiatric disorders have been
67 conducted to date.

68 **Methods:** The targeted study cohort will consist of adults (>18 years) who meet the DSM-5 diagnostic criteria
69 for either (1) depressive disorders, (2) anxiety disorders, or (3) obsessive-compulsive and related disorders.
70 Patients will be assigned in a 1:1 ratio to either a “telepsychiatry group” (at least 50% of visits to be conducted

71 using telemedicine, with at least one face-to-face treatment [FTF] every six months) or an “FTF group” (all
72 visits to be conducted FTF, with no telemedicine). Both groups will receive the usual treatment covered by
73 public medical insurance. The study will utilize a master protocol design in that there will be primary and
74 secondary outcomes for the entire group regardless of diagnosis, as well as the outcomes for each individual
75 disorder group.

76 **Discussion:** This study will be a non-inferiority trial to test that the treatment effect of telepsychiatry is not
77 inferior to that of FTF alone. This study will provide useful insights into the effect of the COVID-19 pandemic
78 on the practice of psychiatry.

79 **Trial Registration:** jRCT1030210037, Japan Registry of Clinical Trials (jRCT)

80

81 **Keywords:** telepsychiatry, depression, anxiety disorder, obsessive-compulsive disorder, master protocol

82

83 **Abbreviations:** COVID-19, the 2019 novel coronavirus disease; J-PROTECT, Japanese Project for
84 Telepsychiatry Evaluation during COVID-19: Treatment Comparison Trial; DSM-5, Diagnostic and Statistical
85 Manual of Mental Disorders, Fifth Edition; FTF, face-to-face treatment; jRCT, Japan Registry of Clinical Trials;
86 OCD, obsessive-compulsive disorder; SF36MCS: MOS36-Item Short-Form Health Survey Mental Component
87 Summary; SF36: MOS 36-Item Short-Form Health Survey; WAI: Working Alliance Inventory; CSQ: Client

88 Satisfaction Questionnaire; EQ-5D: EuroQol 5 Dimension; HAMD: Hamilton Depression Rating Scale;
89 HAMA: Hamilton Anxiety Rating Scale; YBOCS: Yale-Brown Obsessive Compulsive Scale; EDC: electronic
90 data capture; ePRO: electronic patient-reported outcome ; QOL: quality of life.

91

92

93 **1. INTRODUCTION**

94 The 2019 novel coronavirus disease (COVID-19) pandemic, which is raging worldwide, has had significant
95 direct and indirect impacts on mental health. The incidence of symptoms, such as anxiety, depression, and
96 obsessive–compulsive disorder (OCD), in the general population is reportedly higher than during pre-pandemic
97 times as a result of the effects of lockdowns and other restrictions on going out, sudden unemployment, and
98 frequent exposure to related topics through news associated with the COVID-19 pandemic [1-2]. People
99 infected with COVID-19 also reportedly have a higher risk of developing psychiatric disorders, and people with
100 a history of psychiatric disorders have a higher diagnosis rate of COVID-19 infection [3]. This situation suggests
101 that psychiatric care is becoming increasingly important under the COVID-19 pandemic.

102 However, during the COVID-19 pandemic, patients may refrain from visiting hospitals because of fears of
103 infection, and hospitals may stop performing outpatient consultations. According to a survey conducted by
104 WHO in 130 countries, 93% of the countries surveyed reported obstacles to providing psychiatric and mental

105 health services [4]. Under these circumstances, it is important to find ways to continue the provision of
106 psychiatric care. In past epidemics of infectious diseases, telemedicine has been used to prevent infection among
107 healthcare workers by using the telephone and video calls to conduct consultations [5]. During the recent
108 pandemic, telemedicine has attracted attention as a way of continuing medical care while preventing infection,
109 and its use has rapidly expanded due to deregulation in many countries [6].

110 In psychiatry, outpatient care is mainly conducted in the form of in-person conversations; therefore, doctor-
111 to-patient telemedicine, in which patients are treated remotely via videophone, is easy to apply in this field. For
112 this reason, telemedicine was popular in the field of psychiatry even before the COVID-19 pandemic [7]. There
113 have also been many studies comparing the effectiveness of telepsychiatry with face-to-face (FTF) treatment,
114 and telepsychiatry can reportedly provide equivalent or better treatment effects, patient satisfaction, and
115 improved medication adherence, compared with FTF treatment [8-10]. However, most of the existing studies
116 have focused on only a single disorder, such as depression or PTSD, or on experimental trials that differ from
117 real-world clinical practice, and few large pragmatic trials examining multiple psychiatric disorders have been
118 reported worldwide.

119 As COVID-19 is expected to take some time to fully resolve, verifying whether telemedicine is as effective
120 as FTF treatment in real-world clinical practice for the treatment of depression, anxiety, and OCD in existing
121 clinical settings is of great importance, particularly since increases in the diagnosis or exacerbation of these

122 conditions have been reported in response to the circumstances created by the COVID-19 pandemic.

123

124 **2. Method**

125 *2.1. Design Overview*

126 Patients will be assigned in a 1:1 ratio to either a “telepsychiatry group” (at least 50% of visits to be
127 conducted by telemedicine, with at least one FTF every six months) or an “FTF group” (all visits to be FTF,
128 with no telemedicine). Both groups will receive the usual treatment covered by public medical insurance. The
129 interval between visits will be at the discretion of the psychiatrist in charge. This study will have a master
130 protocol with primary and secondary outcomes for the entire group as well as outcomes for each individual
131 disorder group.

132 The main objective of this study will be to show that the telepsychiatry group is non-inferior to the FTF
133 group after 6 months of practice in patients with depressive disorder, anxiety disorder, or OCD and related
134 disorders.

135 *2.2. Participants*

136 This study will be a multi-site, prospective randomized controlled trial. Participants will be recruited at 17
137 medical institutions that provide psychiatric services in 11 different prefectures in Japan. Patient recruitment
138 will be conducted at the following locations and medical institutions: Tokyo (Keio University Hospital,

139 Himorogi Psychiatric Institute); Kanagawa (Yokohama City University Hospital, Shioiri Mental Clinic, Amagai
140 Mental Clinic, Kanazawabunko Yell Clinic); Fukushima (Asaka Hospital); Miyagi (Tohoku University
141 Hospital); Kyoto (University Hospital Kyoto Prefectural University of Medicine); Osaka (Osaka Medical and
142 Pharmaceutical University Hospital, Neyagawa Sanatorium); Tochigi (Ashikaga Red Cross Hospital);
143 Yamagata (Sato Hospital); Miyazaki (Takamiya Hospital); Shizuoka (Numazu Chuo Hospital); and Chiba
144 (International University of Health and Welfare University Narita Hospital, Gakuji-kai Kimura Hospital).

145 The inclusion criteria for participants will be as follows: 1) patients who meet the Diagnostic and Statistical
146 Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for depressive disorders, anxiety disorders, or OCD
147 and related disorders and are outpatients at a participating medical institution; 2) patients who are 18 years old
148 or older at the time of obtaining consent; 3) patients who need continuous treatment for the next 6 months or
149 more (at the discretion of the attending physician); 4) patients who have a smart phone or PC and have access
150 to video calling over the Internet (even if it is only available with family support); 5) patients whose psychiatric
151 conditions are stable enough to receive telepsychiatry by clinical judgement of the attending physician; 6)
152 patients whose psychiatric conditions are stable enough to have sufficient capacity provide consent by clinical
153 judgement of the attending physician; and 7) patients who have provided written consent to participate in the
154 study. For patients who are minors (less than 20 years of age) , written consent must be obtained from the
155 patient and his/her guardian. Exclusion criteria include: 1) patients who are likely to require unscheduled or

156 urgent visits to the hospital in addition to regular visits because of emergent suicidal ideation, anxiety or
157 agitation; and 2) patients who have difficulty managing an emergency visit by themselves when their psychiatric
158 conditions deteriorate (e.g., the hospital is located far away). Researchers will obtain written informed consent
159 from all the participants. The participants will be able to leave the study at any time.

160 *2.3. Randomization*

161 Patients who have given their consent to participate in this study will be randomly assigned in a 1:1 ratio to
162 the “Telepsychiatry group” or the “FTF group” for treatment during the study period. In this study, to avoid
163 inter-institutional differences and biases in the types of disorders among the groups, randomization process is
164 carried out by a blinded, independent third party using a modified minimization method with a biased-coin
165 assignment balanced for age group (60 years old or older, or younger), gender (male or female), target disorder,
166 and participating institution. In addition, the allocation results will not be disclosed to the central evaluator to
167 minimize bias.

168 *2.4. Assessment Schedule*

169 The assessment schedule is presented in Table 1. After randomization, participants will be assessed with the
170 SF36MCS at baseline and at weeks 12 and 24. The duration of each patient’s participation in the study is
171 estimated to be approximately 6 to 7 months, including the allowance period for the prescribed visits.

172 *2.5. Primary Outcomes*

173 The primary outcome is the 36-Item Short Form Health Survey Mental Component Summary (SF36MCS)
174 measured at baseline and at weeks 12 and 24. We will examine whether these changes differ between the
175 Telepsychiatry and FTF groups. The SF36MCS is a self-administered rating scale to which patients respond via
176 a dedicated application.

177 *2.6. Secondary Outcome*

178 The secondary outcomes are the following 12 items: 1) MOS 36-Item Short-Form Health Survey (SF36)
179 (assessed at baseline and at weeks 12 and 24); 2) dropout rate (in the Telepsychiatry group, if the patient stops
180 telepsychiatry and switches to FTF only, the patient will be considered to have dropped out of the Telepsychiatry
181 group; 3) Working Alliance Inventory (WAI) scores as treatment alliance; 4) Client Satisfaction Questionnaire
182 (CSQ) scores as satisfaction; 5) adverse events; 6) costs (Self-administered questionnaire on costs associated
183 with medical visits, etc.); 7) EQ-5D (EuroQol 5 Dimension); 8) degree of anxiety about COVID-19; 9)
184 comments about telepsychiatry (or central evaluation by telemedicine); 10) for the depressive disorder group,
185 Hamilton Depression Rating Scale (HAMD); 11) for the anxiety disorder group, the Hamilton Anxiety Rating
186 Scale (HAMA); and 12) for the OCD and related disorders group, the Yale-Brown Obsessive Compulsive Scale
187 (YBOCS).

188 *2.7. Sample Size*

189 The primary outcome of the study is health-related quality of life as assessed using the SF36MCS, which

190 will be evaluated at baseline and at weeks 12 and 24. The sample size is based on previous psychiatric
191 intervention studies (including psychotherapy and electroconvulsive therapy interventions, but not studies
192 comparing telepsychiatry and FTF), in which the evaluation period was 6 months [11-16]. In existing studies,
193 the mean SF36MCS ranged from 30 to 50 and the standard deviation from 9 to 14.

194 In the present study, assuming that the SF36MCS of the telemedicine and FTF groups at 6 months is 45 (no
195 difference between the two groups), with a standard deviation of 12, and a non-inferiority margin of 5, the
196 required number of patients in each group would be 92 under the conditions of 80% power and a one-sided
197 significance level of 2.5%.

198 In this study, the dropout rate is expected to be low because the primary psychiatrist who have been treating
199 the patients up to the time of the study will continue to be in charge of the treatment regardless of whether the
200 patients are treated in the Telepsychiatry group or in the FTF group. Assuming a dropout rate of about 10%, the
201 total number of patients will be 200, or 100 in each group.

202 *2.8. Data Collection and Management*

203 Data on the SF36MCS, SF36, treatment alliance, satisfaction, cost, EQ-5D, and degree of anxiety about
204 COVID-19 will be collected as self-administered patient-reported outcome measures. We will construct and
205 operate a system to store these data directly using electronic data capture (EDC) and an electronic patient-
206 reported outcome (ePRO). We will use "cubeCDMS" by CRScube Inc. for EDC and "cubePro" by CRScube

207 Inc. for ePRO. The participants will install the ePRO application on their smartphones, etc., access the
208 questionnaire included in the application, and enter and transmit the data. For the HAMD, HAMA, and YBOCS,
209 remote centralized ratings performed through a video camera feed will be used. Evaluators must have completed
210 a total of at least 30 hours of training on these evaluation items, and the evaluator will assess the examinees
211 through a video camera feed at the time of each visit. In addition, as an optional part of the study, both FTF
212 evaluations and centralized ratings for HAMD, HAMA, and YBOCS will be performed for patients who are
213 willing to participate, so as to validate the centralized ratings.

214 *2.9. Statistical analysis*

215 The analyses of the primary and secondary outcomes will be performed in full analysis set (FAS), which
216 includes all patients who took at least one SF36MCS assessment during the study, do not present any serious
217 violation of the study protocol, and have data collected after treatment commencement. For the baseline
218 characteristics, summary statistics will comprise frequencies and proportions for categorical variables, and
219 means and standard deviations for continuous variables. The patient characteristics will be compared using a
220 chi-square test for categorical variables, and a t test or Wilcoxon rank sum test for continuous variables.

221 For the primary analysis, aimed at comparing treatment effects, the least square mean and its 95% confidence
222 interval (CI) will be estimated using a mixed-effects model for repeated measurements (MMRM). No
223 imputation of missing data was performed. The MMRM model will include treatment, visit, treatment-by-visit

224 interaction, and baseline SF36MCS. An unstructured covariance matrix will be assumed to model the within-
225 patient variance and estimation was performed by restricted maximum likelihood method. Based on the model,
226 the result of the SF36MCS at 6 months is expressed with point estimate for group difference and one-sided
227 confidence interval with significance level of 2.5%. Non-inferiority is to be demonstrated if the upper boundary
228 of this confidence interval does not exceed the non-inferiority margin of 5.

229 The secondary analysis will be performed in the same manner as the primary analysis. All comparisons are
230 planned and all p values will be two sided. P values < 0.05 will be considered statistically significant. All
231 statistical analyses will be performed using the SAS software version 9.4 (SAS Institute, Cary, NC, USA). The
232 statistical analysis plan (SAP) will be developed by the principal investigator and the biostatistician before
233 completion of patient recruitment and data fixation.

234 **3. Results**

235 The trial began in April 2021. Recruitment goals are on target to date, and the trial is projected to be
236 completed in March 2023. The trial is registered at jRCT1030210037.

237

238 **4. Discussion**

239 The J-PROTECT study is an important study in both the psychiatric and telemedicine fields, as the COVID-
240 19 outbreak is far from under control. The wide practice of telemedicine in this field is meaningful as an effective

241 countermeasure against infection and to prove that telepsychiatry is effective for the treatment of psychiatric
242 disorders that can worsen during a pandemic. As mentioned above, many studies comparing telepsychiatry with
243 FTF treatment have focused on specific disorders or specific treatments, such as CBT, but few studies have
244 examined multiple disorders simultaneously. For example, O'Reilly et al. randomly assigned 495 outpatients to
245 FTF treatment or telepsychiatry and followed them for up to 4 months; they reported that telepsychiatry
246 provided the same clinical outcome and satisfaction as FTF treatment, but at a lower cost [17]. In another study,
247 De Las Curevas et al. randomly assigned 140 outpatients to FTF treatment or telepsychiatry with a 24-week
248 follow-up period and reported that the efficacy of telepsychiatry was comparable to that of FTF treatment [18].
249 The novelty of the present study is that it will be the first pragmatic trial of telepsychiatry in Japan, a country
250 that provides universal health insurance that allows free access to medical services with relatively low cost. It
251 will also be a multi-center, multi-regional study, unlike previous pragmatic trials of multiple psychiatric
252 disorders. Since the degree and content of telepsychiatry regulation varies in each country [6], showing that
253 telepsychiatry is equally effective in different regulatory and cultural settings will be important to promote its
254 use appropriately.

255 In considering the study design, several issues needed to be taken into account. First, the rationale for
256 selecting SF36MCS as the primary outcome in this study was that it was necessary to establish an outcome that
257 encompassed depressive disorder, anxiety disorder, and OCD and related disorders and that was in use at many

258 psychiatric clinical studies as a health-related quality of life (QOL), which is a superordinate concept for the
259 severity of all illnesses [11-16]. Next, the reason why we set the percentage of telemedicine in the telepsychiatry
260 group to be more than 50% is to allow room for the use of both FTF and telepsychiatry depending on the patient's
261 condition, just as in regular medical care. The Japanese government guidelines also do not recommend the
262 continuation of long-term treatment with telemedicine alone[19].

263 The limitations of this study are as follows. First, we targeted three disorder groups, namely depressive
264 disorders, anxiety disorders, and OCD and related disorders. In addition to targeting three disorders in one trial,
265 the demographic characteristics of the participants may vary over a wide range. This may lead to difficulty in
266 finding a comparative effect size of telemedicine; however, this is an inherent difficulty of pragmatic trials, and
267 limiting participation to a specific patient population may limit the generalizability of the results. Related to this
268 point, IT literacy might be the largest modulator of the results, and since Japan is a world-leading aging society,
269 this fact is of particular consideration. Elderly people generally experience more hurdles to telemedicine because
270 of IT literacy issues [20]. By randomizing the whole population, we reduce the risk of the impact of this possible
271 modulator. At the same time, by asking the participants regarding their impressions or hurdles regarding
272 telemedicine utilization in a free-answer format, we hope to gather information that will enable us to help elderly
273 or low-IT literacy patients to take advantage of telemedicine in the future. Finally, the implementation of this
274 study may be affected by the status of the COVID-19 pandemic. If the pandemic becomes serious, there is a

275 risk that hospitals will suspend FTF treatment or that patients will refuse to come to the hospital for fear of the
276 risk of infection. In any case, we will implement an appropriate combination of telepsychiatry and FTF treatment,
277 while prioritizing the interests of the patients.

278

279 **Ethics approval and consent to participate**

280 This study was approved by the Institutional Review Board of the National Center of Neurology and
281 Psychiatry and the participating medical facilities. Researchers will obtain written informed consent from all
282 the participants. Participants are able to leave the study at any time.

283

284 **Funding**

285 This research is supported by the Japan Agency for Medical Research and Development (AMED) under Grant
286 Number JP21dk0307098. The funding source did not participate in the design of this study and will not have
287 any hand in the study's execution, analyses, or submission of results.

288 Japan Agency for Medical Research and Development (AMED) 20F Yomiuri Shimbun Bldg. 1-7-1 Otemachi,
289 Chiyoda-ku, Tokyo 100-0004 Japan Tel: +81-3-6870-2200, Fax: +81-3-6870-2241, Email: jim-u-a
290 sk@amed.go.jp.

291

292 **Authors' contributions**

293 **Taishiro Kishimoto** : Conceptualization, Methodology, Writing - Review & Editing, Funding acquisition,

294 **Shotaro Kinoshita**: Writing - Original draft preparation. **Shogyoku Bun**: Methodology, Investigation, Writing

295 - Review & Editing, **Yasunori Sato**: Methodology, Formal analysis, **Momoko Kitazawa**: Methodology,

296 Writing - Review & Editing, **Toshiaki Kikuchi**: Methodology, Investigation, **Mitsuhiro Sado**: Methodology,

297 Investigation, **Akihiro Takamiya**: Methodology, Investigation, **Masaru Mimura**: Supervision, **Takashi**

298 **Nakamae**: Methodology, Investigation, **Yoshinari Abe**: Methodology, Investigation, **Tetsufumi Kanazawa**:

299 Methodology, Investigation, **Hiroaki Tomita**: Methodology, Investigation, **Koichi Abe**: Methodology,

300 Investigation, **Akitoyo Hishimoto**: Methodology, Investigation, **Takeshi Asami**: Methodology, Investigation,

301 **Akira Suda**: Methodology, Investigation, **Yoshinori Watanabe**: Methodology, Investigation, **Toru Amagai**:

302 Methodology, Investigation, **Kei Sakuma**: Methodology, Investigation, **Hisashi Kida**: Methodology,

303 Investigation, **Michitaka Funayama**: Methodology, Investigation, **Hiroshi Kimura**: Methodology,

304 Investigation, **Aiko Sato**: Methodology, Investigation, **Soichiro Fujiwara**: Methodology, Investigation,

305 **Kiichiro Nagao**: Methodology, Investigation, **Naoya Sugiyama**: Methodology, Investigation, **Maki**

306 **Takamiya**: Methodology, Investigation, **Hideyuki Kodama**: Methodology, Investigation, **Takaharu**

307 **Azekawa**: Methodology, Investigation.

308 All authors critically revised the manuscript, and approved the manuscript to be published, and agree to be

309 accountable for all aspects of the work in ensuring the questions related to the accuracy or integrity of any part
310 of the work are appropriately investigated and resolved.

311

312 **Declaration of competing interest**

313 The authors declare the following financial interests/personal relationships which may be considered as
314 potential competing interests:

315 T. Kishimoto: Research grant funding, Micin.

316 T. Nakamae: Provided with a telemedicine system, Medley.

317 Y. Abe: Provided with a telemedicine system, Medley.

318

319 **Acknowledgements**

320 The authors are grateful to Dr. Kazunari Yoshida, Dr. Toshiro Horigome, Dr. Mayu Fujikawa, Ms. Kumiko Hiza,

321 Ms. Hiromi Mikami, Ms. Saki Hattori, Mr. Masao Takaishi, Mr. Satoshi Tsujimura, Mr. Hajime Tamura, Ms.

322 Junko Suzuki, Ms. Keiko Komiyada, Dr. Anri Watanabe, Dr. Yoshihiro Matsumoto, Ms. Satoko Kimura, Ms.

323 Haruka Okamoto, Dr. Kyosuke Sawada, Ms. Yuka Oba, Mr. Satoshi Tsujimura, Ms. Shii Sagae, Mr. Kiyoji

324 Nagao, Mr. Ryuhei Terashi, Ms. Sumako Onishi, Ms. Mayumi Hiruma, Ms. Junko Kannari, Ms. Kanako Sasao,

325 Ms. Ayumi Konishi, Ms. Nobuko Haga, Mr. Nobuhiko Noguchi, Mr. Kosuke Hino, Mr. Yuya Igarashi, Dr.

326 Kenichi Goto for supporting data collection and management in this study.

327

328 **References**

329 [1] Xiong J, Lipsitz O, Nasri F, Lui LMW, Gill H, Phan L, Chen-Li D, Iacobucci M, Ho R, Majeed A,

330 McIntyre RS. Impact of COVID-19 pandemic on mental health in the general population: A systematic review.

331 *J Affect Disord.* 2020 Dec 1;277:55-64. doi: 10.1016/j.jad.2020.08.001.

332 [2] Jelinek L, Moritz S, Miegel F, Voderholzer U. Obsessive-compulsive disorder during COVID-19: Turning

333 a problem into an opportunity? *J Anxiety Disord.* 2021 Jan;77:102329. doi: 10.1016/j.janxdis.2020.102329.

334 [3] Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and

335 psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. *Lancet Psychiatry.*

336 2021 Feb;8(2):130-140. doi: 10.1016/S2215-0366(20)30462-4.

337 [4] World Health Organization. The impact of COVID-19 on mental, neurological and substance use services:

338 results of a rapid assessment. URL : <https://apps.who.int/iris/rest/bitstreams/1310579/retrieve> (accessed :

339 2021/5/7)

340 [5] Keshvaridoost S, Bahaadinbeigy K, Fatehi F. Role of Telehealth in the Management of COVID-19:

341 Lessons Learned from Previous SARS, MERS, and Ebola Outbreaks. *Telemed J E Health.* 2020 Jul;26(7):850-

342 852. doi: 10.1089/tmj.2020.0105.

- 343 [6] Kinoshita S, Cortright K, Crawford A, Mizuno Y, Yoshida K, Hilty D, Guinart D, Torous J, Correll CU,
344 Castle DJ, Rocha D, Yang Y, Xiang YT, Kølbæk P, Dines D, ElShami M, Jain P, Kallivayalil R, Solmi M, Favaro
345 A, Veronese N, Seedat S, Shin S, Salazar de Pablo G, Chang CH, Su KP, Karas H, Kane JM, Yellowlees P,
346 Kishimoto T. Changes in telepsychiatry regulations during the COVID-19 pandemic: 17 countries and regions'
347 approaches to an evolving healthcare landscape. *Psychol Med.* 2020 Nov 27;1-8. doi:
348 10.1017/S0033291720004584. Epub ahead of print.
- 349 [7] World Health Organization. Telemedicine: opportunities and developments in Member States: report on
350 the second global survey on eHealth 2009. URL :
351 http://www.who.int/goe/publications/goe_telemedicine_2010.pdf (accessed : 2021/5/7)
- 352 [8] Salmoiraghi A, Hussain S. A Systematic Review of the Use of Telepsychiatry in Acute Settings. *J*
353 *Psychiatr Pract.* 2015 Sep;21(5):389-93. doi: 10.1097/PRA.000000000000103.
- 354 [9] Hubley S, Lynch SB, Schneck C, Thomas M, Shore J. Review of key telepsychiatry outcomes. *World J*
355 *Psychiatry.* 2016 Jun 22;6(2):269-82. doi: 10.5498/wjp.v6.i2.269.
- 356 [10] Basit SA, Mathews N, Kunik ME. Telemedicine interventions for medication adherence in mental
357 illness: A systematic review. *Gen Hosp Psychiatry.* 2020 Jan-Feb;62:28-36. doi:
358 10.1016/j.genhosppsy.2019.11.004.
- 359 [11] Fortney JC, Pyne JM, Mouden SB, Mittal D, Hudson TJ, Schroeder GW, Williams DK, Bynum CA,

- 360 Mattox R, Rost KM. Practice-based versus telemedicine-based collaborative care for depression in rural
361 federally qualified health centers: a pragmatic randomized comparative effectiveness trial. *Am J Psychiatry*.
362 2013 Apr;170(4):414-25. doi: 10.1176/appi.ajp.2012.12050696.
- 363 [12] Connolly Gibbons MB, Gallop R, Thompson D, Luther D, Crits-Christoph K, Jacobs J, Yin S, Crits-
364 Christoph P. Comparative Effectiveness of Cognitive Therapy and Dynamic Psychotherapy for Major
365 Depressive Disorder in a Community Mental Health Setting: A Randomized Clinical Noninferiority Trial.
366 *JAMA Psychiatry*. 2016 Sep 1;73(9):904-11. doi: 10.1001/jamapsychiatry.2016.1720. Erratum in: *JAMA*
367 *Psychiatry*. 2017 Jan 1;74(1):107.
- 368 [13] McCall WV, Lisanby SH, Rosenquist PB, Dooley M, Husain MM, Knapp RG, Petrides G, Rudorfer MV,
369 Young RC, McClintock SM, Mueller M, Prudic J, Greenberg RM, Weiner RD, Bailine SH, Youssef NA,
370 McCloud L, Kellner CH; CORE/PRIDE Work Group. Effects of continuation electroconvulsive therapy on
371 quality of life in elderly depressed patients: A randomized clinical trial. *J Psychiatr Res*. 2018 Feb;97:65-69.
372 doi: 10.1016/j.jpsychires.2017.11.001.
- 373 [14] Lovell K, Bower P, Gellatly J, Byford S, Bee P, McMillan D, Arundel C, Gilbody S, Gega L, Hardy G,
374 Reynolds S, Barkham M, Mottram P, Lidbetter N, Pedley R, Molle J, Peckham E, Knopp-Hoffer J, Price O,
375 Connell J, Heslin M, Foley C, Plummer F, Roberts C. Low-intensity cognitive-behaviour therapy interventions
376 for obsessive-compulsive disorder compared to waiting list for therapist-led cognitive-behaviour therapy: 3-

- 377 arm randomised controlled trial of clinical effectiveness. PLoS Med. 2017 Jun 27;14(6):e1002337. doi:
378 10.1371/journal.pmed.1002337.
- 379 [15] Rollman BL, Belnap BH, Mazumdar S, Abebe KZ, Karp JF, Lenze EJ, Schulberg HC. Telephone-
380 Delivered Stepped Collaborative Care for Treating Anxiety in Primary Care: A Randomized Controlled Trial. J
381 Gen Intern Med. 2017 Mar;32(3):245-255. doi: 10.1007/s11606-016-3873-1.
- 382 [16] Bennebroek Evertsz' F, Sprangers MAG, Sitnikova K, Stokkers PCF, Ponsioen CY, Bartelsman JFWM,
383 van Bodegraven AA, Fischer S, Depla ACTM, Mallant RC, Sanderman R, Burger H, Bockting CLH.
384 Effectiveness of cognitive-behavioral therapy on quality of life, anxiety, and depressive symptoms among
385 patients with inflammatory bowel disease: A multicenter randomized controlled trial. J Consult Clin Psychol.
386 2017 Sep;85(9):918-925. doi: 10.1037/ccp0000227.
- 387 [17] O'Reilly R, Bishop J, Maddox K, Hutchinson L, Fisman M, Takhar J. Is telepsychiatry equivalent to
388 face-to-face psychiatry? Results from a randomized controlled equivalence trial. Psychiatr Serv. 2007
389 Jun;58(6):836-43. doi: 10.1176/ps.2007.58.6.836.
- 390 [18] De Las Cuevas C, Arredondo MT, Cabrera MF, Sulzenbacher H, Meise U. Randomized clinical trial of
391 telepsychiatry through videoconference versus face-to-face conventional psychiatric treatment. Telemed J E
392 Health. 2006 Jun;12(3):341-50. doi: 10.1089/tmj.2006.12.341.
- 393 [19] Ministry of Health, Labour and Welfare. The guidelines for appropriate operation of online medicine

394 [in Japanese]. <https://www.mhlw.go.jp/content/000534254.pdf> (accessed : 2021/5/7)

395 [20] Hargittai, E., Piper, A.M. & Morris, M.R. From internet access to internet skills: digital inequality among

396 older adults. *Univ Access Inf Soc* 18, 881–890 (2019). <https://doi.org/10.1007/s10209-018-0617-5>

397

398

399

400 **Table 1. Schedule for data collection and evaluations during the study’s observation period**

401

Visit for medical care (FTF or telepsychiatry)	 <p>After obtaining consent, patients will be assigned to either the FTF group or the Telepsychiatry group, and they will continue to receive treatment for 6 months. (The interval between visits will be determined by the attending physician.)</p>		
/	Visit 1	Visit 2	Visit 3
	Baseline	12 Weeks (3 Months)	24 Weeks (6 Months)
Patient background	●		
SF36	○	○	○
Working Alliance Inventory (WAI)		○	○
Client Satisfaction Questionnaire (CSQ)		○	○
Adverse events			
Costs (Self-administered questionnaire on costs associated with medical visits, etc.)	○	○	○
EQ-5D	○	○	○

Degree of anxiety about COVID-19	○	○	○
Comments about telepsychiatry			○
HAMD (Depressive disorders only)	☆	☆	☆
HAMA (Anxiety disorders only)	☆	☆	☆
YBOCS (OCD and related disorders only)	☆	☆	☆

402

●: Both groups receive FTF treatment.

403

○: In both groups, the evaluation was conducted using input from smartphones and tablets (via ePRO).

404

405

☆: For each disorder group, outcomes unique to each disorder will be investigated. A centralized evaluation system will be adopted in which patients and evaluators will be connected remotely. For patients with partial cooperation, both face-to-face evaluation and telemedicine with central evaluation will be conducted for the purpose of verifying the reliability of the outcomes of each disorder group.

406

407

408

409

410

411